I B Vergote1, B Lund2, U Peen3, Z Umajuridze4, M Mau-Sorensen4, A Kranich5, E Van Nieuwenhuysen6, C Haslund2, T Nottrup4, S N Han6, N Concin6, T J Unger7, Y Chai7, N Au7, T Rashal7, A Joshi7, M Crochiere7, Y Landesman7, J Shah7, S Shacham7, M Kauffman7, M R Mirza7. 1. Department of Obstetrics and Gynaecology, Division of Gynecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium, European Union. Electronic address: ignace.vergote@uzleuven.be. 2. Aalborg University Hospital, Aalborg, Denmark. 3. Herlev University Hospital, Herlev, Denmark. 4. Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 5. GSO Hamburg, Germany. 6. Department of Obstetrics and Gynaecology, Division of Gynecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium, European Union. 7. Karyopharm Therapeutics Newton, MA, USA.
Abstract
BACKGROUND:Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies. METHODS: In this phase 2 trial, patients received selinexor (35 or 50 mg/m2 twice-weekly [BIW] or 50 mg/m2 once-weekly [QW]) in 4-week cycles. Primary endpoint was disease control rate (DCR) including complete response (CR), partial response (PR) or stable disease (SD) ≥12 weeks. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. RESULTS:114 patients with ovarian (N = 66), endometrial (N = 23) or cervical (N = 25) cancer were enrolled. Median number of prior regimens for ovarian, endometrial and cervical cancer was 6 (1-11), 2 (1-5), and 3 (1-6) respectively. DCR was 30% (ovarian 30%; endometrial 35%; cervical 24%), which included confirmed PRs in 8%, 9%, and 4% of patients with ovarian, endometrial, and cervical cancer respectively. Median PFS and OS for patients with ovarian, endometrial and cervical cancer were 2.6, 2.8 and 1.4 months, and 7.3, 7.0, and 5.0 months, respectively. Common Grade 3/4 adverse events (AEs) were thrombocytopenia (17%), fatigue (14%), anemia (10%), nausea (9%) and hyponatremia (9%). Patients with ovarian cancer receiving50 mg/m2 QW had fewer high-grade AEs with similar efficacy as BIW treatment. CONCLUSIONS:Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care.
RCT Entities:
BACKGROUND:Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies. METHODS: In this phase 2 trial, patients received selinexor (35 or 50 mg/m2 twice-weekly [BIW] or 50 mg/m2 once-weekly [QW]) in 4-week cycles. Primary endpoint was disease control rate (DCR) including complete response (CR), partial response (PR) or stable disease (SD) ≥12 weeks. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. RESULTS: 114 patients with ovarian (N = 66), endometrial (N = 23) or cervical (N = 25) cancer were enrolled. Median number of prior regimens for ovarian, endometrial and cervical cancer was 6 (1-11), 2 (1-5), and 3 (1-6) respectively. DCR was 30% (ovarian 30%; endometrial 35%; cervical 24%), which included confirmed PRs in 8%, 9%, and 4% of patients with ovarian, endometrial, and cervical cancer respectively. Median PFS and OS for patients with ovarian, endometrial and cervical cancer were 2.6, 2.8 and 1.4 months, and 7.3, 7.0, and 5.0 months, respectively. Common Grade 3/4 adverse events (AEs) were thrombocytopenia (17%), fatigue (14%), anemia (10%), nausea (9%) and hyponatremia (9%). Patients with ovarian cancer receiving 50 mg/m2 QW had fewer high-grade AEs with similar efficacy as BIW treatment. CONCLUSIONS:Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care.
Authors: Jennifer R Landes; Stephen A Moore; Brooke R Bartley; Hung Q Doan; Peter L Rady; Stephen K Tyring Journal: J Cancer Res Clin Oncol Date: 2022-08-08 Impact factor: 4.322
Authors: Kyaw Z Thein; Daniel D Karp; Apostolia Tsimberidou; Jing Gong; Selma Sulovic; Jatin Shah; Denái R Milton; David S Hong; Filip Janku; Lacey McQuinn; Bettzy A Stephen; Rivka Colen; Brett W Carter; Timothy A Yap; Sarina A Piha-Paul; Siqing Fu; Funda Meric-Bernstam; Aung Naing Journal: Invest New Drugs Date: 2021-09-25 Impact factor: 3.651
Authors: Jingshan Ho; Valerie Heong; Wei Peng Yong; Ross Soo; Cheng Ean Chee; Andrea Wong; Raghav Sundar; Yee Liang Thian; Anil Gopinathan; Mei Yan Pang; Priscillia Koe; Santhiay Nathan Jeraj; Phyu Pyar Soe; Mu Yar Soe; Tiffany Tang; Matthew C H Ng; David W M Tai; Tira J Y Tan; Hongmei Xu; Hua Chang; Yosef Landesman; Jatin Shah; Sharon Shacham; Soo Chin Lee; Daniel S W Tan; Boon Cher Goh; David S P Tan Journal: Ther Adv Med Oncol Date: 2022-04-11 Impact factor: 8.168
Authors: Kyaw Z Thein; Sarina A Piha-Paul; Apostolia Tsimberidou; Daniel D Karp; Filip Janku; Siqing Fu; Vivek Subbiah; David S Hong; Timothy A Yap; Jatin Shah; Denái R Milton; Lacey McQuinn; Jing Gong; Yanyan Tran; Brett W Carter; Rivka Colen; Funda Meric-Bernstam; Aung Naing Journal: Exp Hematol Oncol Date: 2021-12-29
Authors: Gomaa Mostafa-Hedeab; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Nermeen N Welson; Gaber El-Saber Batiha; Carlos Adam Conte-Junior Journal: Front Pharmacol Date: 2022-04-26 Impact factor: 5.988